CAS NO: | 11103-72-3 |
包装: | 100mg |
市场价: | 1240元 |
Physical Appearance | A solid |
Storage | Store at RT |
M.Wt | 786.35 |
Cas No. | 11103-72-3 |
Formula | H42N14O2Ru3Cl6 |
Solubility | ≥7.86 mg/mL in H2O; insoluble in DMSO; insoluble in EtOH |
Canonical SMILES | [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].N.N.N.N.N.N.N.N.N.N.N.N.N.N.[O].[O].[Ru+2].[Ru+2].[Ru+2] |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
Ruthenium red is a strong inhibitor of Ca2+ transport in mitochondrial, in erythrocyte membrane and in sarcoplasmic reticulum (SR) of rabbit skeletal muscle, with theKm of 4.5μM and 2.0 mM for the two Ca2+-binding sites [1].
By kinetic experiments, there are two high-affinity Ca2+-binding sites face the cytoplasmic portion of the SR membranes, which are located in helical segments clustered in the transmembrane domain of Ca2+-ATPase, forming a Ca2+ channel.
SR vesicles were incubated with 10μM-45Ca2+ and various ruthenium red concentrations for 15 min before being filtered for45Ca counting. The titration curve of Ca2+ binding showed two well-differentiated saturating effects with theKm of 4.5μM and 2.0 mM for the two Ca2+-binding sites. The ability of SR vesicles to bind Ca2+ was decreased by micromolar ruthenium red concentrations [1].
In the investigation of the ability of inhibiting caspsaicin-induced plasma extravasation in the rat trachea, ruthenium red can reduce the amount of plasma extravasation in dose-dependently, with a dose of 5μmol/kg of completely inhibiting [2].
Reference:
[1] Corbalan-Garcia S, Teruel J A, Gomez-Fernandez J C. Characterization of Ruthenium Red-binding sites of the Ca2+-ATPase from sarcoplasmic reticulum and their interaction with Ca2+-binding sites [J]. Biochem J. 1992, 287(3): 767-774.
[2] Brokaw J J, White G W. Characterization of Ruthenium Red as an Inhibitor of Neurogenic Inflammation in the Rat Trachea [J]. Gen Pharmac. 1995, 26(2): 327-331.